ImmuCell
ICCC
10 hedge funds and large institutions have $725K invested in ImmuCell in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, reducing their positions, and 1 closing their positions.
62% more capital invested
Capital invested by funds: $447K → $725K (+$278K)
1.14% more ownership
Funds ownership: 3.95% → 5.09% (+1.1%)
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$122K |
| 2 |
U
UBS
Zurich,
Switzerland
|
+$5.68K |
| 3 |
Renaissance Technologies
New York
|
+$3.91K |
| 4 |
SRC
Shufro Rose & Co
New York
|
+$2.35K |
| 5 |
Morgan Stanley
New York
|
+$1.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
ICCC Hedge Fund Activity: Q3 2013 in Review
10 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q3 2013, worth a combined $725K — up 62% from $447K a quarter earlier.
Fund positioning in ICCC was balanced in Q3 2013: 1 fund opened new positions, 1 closed out, 4 added to existing stakes and 0 trimmed.
The largest buyer was Shepherd Kaplan Krochuk, opening a new position worth an estimated $122K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $1K sold.
- 10 institutional investors held ImmuCell (ICCC) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $725K of ImmuCell stock for Q3 2013, up 62% quarter-over-quarter.
- 1 fund opened new ImmuCell positions in Q3 2013 and 1 closed out, a net change of 0 holders.
- The largest ImmuCell buyer in Q3 2013 was Shepherd Kaplan Krochuk, an estimated $122K added.
- The largest ImmuCell seller in Q3 2013 was Tower Research Capital (TRC), an estimated $1K sold.
Based on aggregated 13F filings for Q3 2013.